Clinical Trial Update: Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating safety, tolerability and effectiveness of DTG/3TC versus BIC/TAF/FTC in ART-naive people with HIV; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Metabolic Syndrome

Drugs mentioned

• Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) (bictegravir/emtricitabine/tenofovir alafenamide)
• Dovato (dolutegravir/lamivudine) (dolutegravir/lamivudine)

Snippet

Sponsor: Instituto Mexicano del Seguro Social | Conditions: HIV Infection, Metabolic Syndrome | Phase 4 | Status: RECRUITING